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It remains controversial whether current antiretroviral therapy (ART) fully suppresses the
cycles of HIV replication and viral evolution in vivo. If replication persists in sanctuary sites
such as the lymph nodes, a high priority should be placed on improving ART regimes to
target these sites. To investigate the question of ongoing viral replication on current ART
regimens, we analyzed HIV populations in longitudinal samples from 10 HIV-1–infected
children who initiated ART when viral diversity was low. Eight children started ART at less
than ten months of age and showed suppression of plasma viremia for seven to nine years.
Two children had uncontrolled viremia for fifteen and thirty months, respectively, before
viremia suppression, and served as positive controls for HIV replication and evolution.
These latter 2 children showed clear evidence of virus evolution, whereas multiple methods
of analysis bore no evidence of virus evolution in any of the 8 children with viremia
suppression on ART. Phylogenetic trees simulated with the recently reported evolutionary
rate of HIV-1 on ART of 6 × 10–4 substitutions/site/month bore no resemblance to the
observed data. Taken together, these data refute the concept that ongoing HIV replication is
common with ART and is the major barrier to curing HIV-1 infection.
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Introduction
Antiretroviral therapy (ART) is known to suppress viremia and 
prolong survival of HIV-1–infected individuals but does not elim-
inate the HIV reservoirs that cause viral rebound after treatment 
is stopped. There has been continued debate about whether the 
HIV reservoir is maintained through the persistence and prolifer-
ation of cells infected before the initiation of ART (1–5), or from 
ongoing viral replication in potential ART sanctuary sites, such as 
lymph nodes (LNs) (6–10), with subsequent trafficking of recently 
infected cells into the blood (10, 11). If ongoing replication in 
tissues maintains the HIV reservoir, then preventing infection 
of new cells by developing antiretrovirals that better penetrate 
sanctuary sites such as LNs would be a high priority. Conversely, 
if current ART is fully effective at blocking full cycles of viral rep-
lication in both tissues and blood, then the elimination of prolif-
erating and long-lived infected cells would be the highest priority 
for achieving an HIV-1 cure. It is therefore critical that the efficacy 
of current ART be fully understood to identify the most appropri-
ate curative strategy.
Prior studies addressing the question of ongoing replication 
have analyzed the evolution of virion RNA or proviral DNA seq-
uences in chronically infected adults as a function of the duration of 
ART (3, 10, 12–15). Such studies have ascribed the success of ART to 
its ability to effectively prevent the infection of new cells by reduc-
ing the in vivo reproductive rate to less than 1 and effectively halting 
viral evolution and preventing the associated development of drug 
resistance (3, 16, 17). The prevention of new rounds of viral repli-
cation is thought to result in the rapid decay of short-lived, virus- 
producing cells and associated plasma viremia, followed by a grad-
ual decay of longer-lived cells (18, 19). These studies, however, have 
not settled the controversy, mainly because the high baseline genet-
ic diversity in chronically infected adults severely limits the ability to 
clearly detect evolutionary changes in viral sequences. We therefore 
turned our attention to perinatally infected infants who were start-
ed on ART when HIV diversity was low (20–24), making it simpler 
to clearly detect mutations that accumulate with viral replication.
To address the issue of ongoing viral replication in patients 
on current ART regimens, we compared single HIV p6, protease, 
and reverse transcriptase (p6-PR-RT) sequences obtained from 
plasma and/or peripheral blood mononuclear cells (PBMCs) near 
the time of ART initiation and after 7 to 9 years of ART in 10 chil-
dren who initiated treatment during early infection and with low 
viral diversity. Eight of the children had viremia suppression on 
ART for the duration of the study, and two did not have viremia 
suppression for fifteen and thirty months and thus served as posi-
tive controls for HIV replication and evolution in vivo.
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over time. One of the two viremic children also had a population 
of sequences after eight years on ART that remained identical to 
the founder virus (Figure 1A; PID ZA001), suggesting that these 
proviruses are in long-lived, possibly proliferating, cells harboring 
the original transmitted variant.
HIV diversity and evolution in children on ART with suppressed 
viremia. The viral populations in the 8 children with fully suppressed 
viremia for the sampling interval were noticeably different from the 
viremic children. In all but 1 of the children, there was no evidence 
of evolution by any method applied (Figure 1, C–J, and Table 1), and 
none of the trees showed populations of divergent sequences on 
separate nodes or longer branches after long-term ART compared 
with those at baseline, consistent with a lack of virus replication and 
evolution during ART. One of the children (PID ZA003) did show 
an increase in viral diversity from 0.04% to 0.10% (P = 0.003) 
(10) over time, but no other test (panmixia or slope of root-to-tip 
distances in ML trees) showed results consistent with evolution (Fig-
ure 1C and Table 1). The NJ tree (Figure 1C) revealed that the differ-
ence in diversity in PID ZA003 between the early and late samples 
was attributable to 1 sequence on a longer branch (indicated with a 
blue arrow in Figure 1C). When this sequence was removed from 
the tree (not shown), the diversity difference became nonsignificant 
(0.04% vs. 0.03%; P = 0.6). The HIV DNA level in this child on long-
term ART was very low (1.5 proviruses per million PBMCs); conse-
quently, only 7 sequences were obtained, increasing the likelihood 
that a single sequence could unduly influence diversity estimates. 
Of note, all 7 sequences, including the variant on the longer branch, 
were included in all other analyses. Overall, the test for panmixia 
and analyses of root-to-tip distances showed no evidence of HIV 
evolution in any child whose viremia was fully suppressed on ART 
from the time of its initiation.
Persistence of HIV in cells infected prior to ART through cellu-
lar proliferation. Populations of identical proviral DNA sequenc-
es were observed after long-term ART in all of the children with 
suppressed viremia and may have been from the proliferation of 
infected cells during ART (1, 31). In all cases, some of the identical 
sequences present after 7 to 9 years of ART were exact matches 
to the baseline variants. Two children (PID ZA003 and ZA004) 
had almost no viral diversity at baseline (0.04% and 0.11% APD, 
respectively), were initiated on ART at approximately 2 months of 
age, and had HIV DNA levels of only 1.5 and 23.6 copies per mil-
lion PBMCs after 8 years on ART. Also, the HIV sequences within 
the infected cells that persisted on ART were essentially identical 
to those at baseline (i.e., no nucleotide divergence was observed 
above the background for SGS [ref. 32]). These examples provide 
Results
Children identified as HIV-1 RNA positive at birth and initiated 
on ART (Supplemental Table 1; supplemental material available 
online with this article; https://doi.org/10.1172/JCI94582DS1) 
as part of the Children with HIV Early Antiretroviral Therapy 
(CHER) trial (25) were studied for evidence of HIV-1 replication 
during ART. We used single-genome amplification and sequenc-
ing (SGS) to compare HIV p6-PR-RT sequences obtained from 
plasma or PBMCs near the time of ART initiation (baseline) and 
after 7 to 9 years on ART (long-term ART) in 10 children (Supple-
mental Table 1). The fragment analyzed is 1.2 kb in length and 
covers the p6 region of gag as well as protease and the first 700 bp 
of reverse transcriptase in the pol gene. The sequences from the 
10 children are shown in neighbor-joining (NJ), p-distance trees 
in Figure 1. Eight had undetectable plasma HIV-1 RNA through-
out the period of observation and had initiated treatment by 10 
months of age (median: 2.45 months; range: 1.8–9.9 months). Two 
children, serving as controls, did not have plasma viremia suppres-
sion on ART for fifteen to thirty months. To look for evidence of 
ongoing viral replication during ART, HIV populations in samples 
taken at baseline were compared with the populations present 
after long-term ART. Three measures of evolution were assessed 
for significant change over time: (a) HIV-1 genetic diversity, mea-
sured as the average pairwise distance (APD), from early infection 
to long-term infection; (b) genetic divergence from the founder 
virus(es) using a test for panmixia (3, 12, 26, 27); and (c) root-to-tip 
distances in maximum-likelihood (ML) trees (3, 12, 27). ML trees 
were rooted in 2 ways: first, on an outgroup (HIV subtype C con-
sensus; www.hiv.lanl.gov), and second, on the majority sequence 
of the baseline sample (Table 1).
HIV diversity and evolution in children with unsuppressed vire-
mia. The HIV populations in all children had very low diversity 
(median APD of 0.20%; range, 0.04%–0.29%) at the first sam-
pling time point (baseline) (Supplemental Table 1 and Table 1) 
(28), and most had a large rake of identical sequences, which was 
consistent with a single transmitted/founder virus (29, 30) and 
provided a low background on which to detect evolution (Figure 
1, Figure 2, and Table 1). The 2 children with unsuppressed vire-
mia for 15 and 30 months following the first sample (Figure 1, A 
and B; patient identifiers [PIDs] ZA001 and ZA002) showed clear 
evidence of HIV evolution: significant increases in viral diversity 
and a low probability of panmixia (Figure 1, A and B, and Table 
1); significantly longer root-to-tip distances in ML trees (Table 1); 
and obvious clusters of sequences on longer branches in NJ trees 
(Figure 1, A and B); indicating the emergence of new viral variants 
Figure 1. Properties of HIV-1 infection in the 10 children studied. HIV sequence diversity was measured as the APD at the indicated time points. Divergence 
was measured using a test for panmixia, with a P value of less than 0.001 considered significant after correcting for multiple comparisons (8), and by mea-
suring the root-to-tip distances of sequences on phylogenetic trees (longer branches over time indicate viral evolution). A 1-sample t test was used to deter-
mine if there was a significant change in APD on ART, and a 2-tailed F test was used to determine whether the root-to-tip slopes were significantly different 
from 0. All branches are shown as the p-distance in the NJ trees. Baseline HIV sequences were either from PBMC DNA (red triangles) or plasma RNA (red 
circles), and sequences for long-term ART were all from PBMC DNA (black triangles), sampled at the indicated time points. Blue brackets show sequences 
with evidence of HIV evolution. Plots to the left of the trees show the plasma HIV RNA viral load (VL) as a function of age. Red and black arrows on the plots 
indicate the time of collection of samples analyzed by SGS. Red vertical arrows indicate the patient’s age at ART initiation. White symbols indicate samples 
with an undetectable VL, plotted at the limit of sensitivity of the assay used. The apparent decline in the level of undetectable VL in some samples is due 
to a switch to an assay with a lower limit of detection. (A and B) Patients with detectable viremia for more than 1 year after the time of the first sample. 
(C–J) Patients with undetectable viremia for all samples taken after the first sample. The blue arrow indicates a sequence that was omitted in 1 sensitivity 
analysis, as discussed in the text. Results from a total of 20 samples are included in this figure.
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and Figure 3A) revealed obvious topological differences (Figure 
3C) and indicated that the evolutionary rate reported in ref. 10 
was grossly overestimated. To show that our simulation model 
accurately reflects the accumulation of mutations in vivo, we per-
formed the same simulation for the children (ZA001 and ZA002) 
who served as replication controls using evolutionary rates calcu-
lated from the change in the root-to-tip distances over time for 
these children. The simulated NJ trees for each control are shown 
in Supplemental Figure 1 and have topologies similar to those of 
the actual trees in Figure 1, A and B. The results of these analyses 
indicate that the more appropriate method for evaluating the pop-
ulation structure and divergence of HIV populations during ART 
is NJ tree construction, which does not make any assumptions 
regarding evolution or impose a time stamp, but only displays the 
absolute genetic differences among variants in the population.
Discussion
The failure to detect any significant change in the HIV population 
for 7 to 9 years in children on ART with sustained suppression of 
viremia provides strong evidence against ongoing replication of 
HIV-1 either in the blood or in sanctuary sites with subsequent 
trafficking of infected cells peripherally, as is expected (10). These 
findings directly refute those purported to show HIV evolution in 
patients on ART (10) and confirm that the HIV reservoir is likely 
maintained largely, if not solely, by the persistence and expansion 
of cells that were infected prior to the initiation of treatment in 
individuals on ART with sustained suppression of viremia. Our 
findings are consistent with those of another report that failed to 
find significant evidence for HIV evolution during ART in chil-
dren by comparing plasma sequences at baseline with virus that 
was produced in the supernatants of cultured resting CD4+ T cells 
(33) after approximately 5 years on ART. The “slow” evolution 
reported (33) included substitutions that were not above the back-
ground from the ex vivo methods used (viral outgrowth followed 
by bulk PCR and cloning).
Using specimens collected from 2 children with known viral 
replication during the sampling interval as positive controls for 
detection of HIV evolution, we were able to demonstrate that HIV 
replication is readily detectable using measurements of diversity, 
divergence, and ML or NJ phylogenetics. Using these same meth-
ods, we showed that there was no evidence for ongoing cycles of 
HIV replication during the 7- to 9-year period of ART in children 
the clearest evidence that HIV did not evolve for 8 years on ART 
and strongly imply that HIV replication is halted by ART in both 
the blood and LNs, since it is known that cells continually traffic 
from the lymphatics into the blood (10, 11). Overall, the analy-
ses for all 8 children indicate that when ART suppresses viremia 
below the limit of detection of assays used clinically, viral replica-
tion is blocked, and only archival variants persist in cells, which 
may expand through cell proliferation, as has been observed in 
adults and children (2, 31).
Comparison of NJ and BEAST phylogenetic analyses. To com-
pare our phylogenetic methods with those used by others (10), we 
also generated trees from the same data set using BEAST (Bayes-
ian evolutionary analysis sampling trees) (http://beast.bio.ed.ac.
uk/) (Figure 3). One example is shown in Figure 3B and is com-
pared with a NJ tree of the same sequences (Figure 1D and Figure 
3A). The sequences are numbered for cross-reference between 
all the trees in Figure 3. It is clear that the time-stamped Bayes-
ian method in BEAST using a strict molecular clock (10) forces the 
appearance of evolution, even in cases in which the populations do 
not vary beyond the level of random variation expected from SGS 
sampling. In addition, identical HIV variants cannot be readily 
identified in trees generated by BEAST using such time-stamped 
parameters, because all sequences are assigned an “evolutionary 
distance” by the program, such that sequences sampled later are 
placed on separate nodes and longer branches than are identical 
sequences present at baseline (2, 31). This artifactual appear-
ance of evolution occurs because a time stamp, associated with 
the sample collection date, is used in the algorithm to generate 
the tree. Thus, the “evolution” in the tree produced by BEAST is 
largely a result of artifacts from algorithmic assumptions that are 
not appropriate for visualizing intra-patient HIV evolution, for 
estimating HIV evolutionary rates in patients on ART, or for draw-
ing conclusions regarding HIV replication during ART.
Simulated NJ tree after 8 years on ART using HIV evolutionary 
rate. To investigate further the accuracy of a previous report (10), 
we made NJ trees that contained both the baseline sequences from 
the same patient (PID ZA004) and the sequences that would be 
present in the blood after 8 years if evolution on ART had occurred 
at the rate recently reported (6.24 × 10–4 substitutions/site/month) 
(10), with trafficking of newly infected cells from LNs to the blood, 
as was previously proposed (10, 11) (Figure 3C). Comparison with 
the actual NJ tree derived from the same sequences (Figure 1D 
Figure 2. HIV-1 diversity as a 
function of age. Changes in 
the APD at baseline compared 
with 7 to 9 years of viremia sup-
pression on ART. The 2 children 
with unsuppressed viremia are 
shown in red and the others in 
black. The heavy dashed lines 
show the linear regression for 
all relevant sequences in aggre-
gate, with the slopes and R2 
values indicated. Results from a 
total of 20 samples are included 
in this figure.
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who have fully suppressed viremia. We also showed that the use 
of the time-stamped Bayesian phylogenetic method using a strict 
molecular clock applied in the program BEAST can generate the 
appearance of HIV evolution, even in sets of identical sequences 
and, therefore, is not an accurate method for addressing the ques-
tion of ongoing HIV replication during ART. It is important to note 
that all our analyses were conducted on blood samples and, as 
such, does not replicate exactly the previous report (10). Thus, it 
is important to continue to investigate HIV diversity and evolution 
in LN samples, although it is widely accepted that the migration of 
cells from LNs to the blood would occur over a 7- to 9-year period 
(10, 11). It should also be noted that most proviruses in samples 
from infected individuals on ART are defective (34, 35) and rep-
resent an evolutionary dead end from which no further sequence 
change is expected. Despite this limitation of clinical sampling, 
our analyses showed that viral replication and evolution were 
readily detectable in children with uncontrolled viremia when 
sampling occurred over a span of more than 1 year.
Our results are consistent with those of previous reports show-
ing that, despite low-level plasma viremia remaining detectable in 
most patients when tested with sufficiently sensitive assays (36), 
previous attempts to reduce low-level plasma viremia through 
antiretroviral treatment intensification were unsuccessful (16, 17). 
The results of these antiretroviral intensification studies provide 
strong evidence that low-level plasma viremia is not indicative of 
ongoing replication but rather arises from intermittent activation 
and virion production from cells that were already infected before 
ART initiation and thus are not affected by ART. The persistence 
of long-lived infected cells has been shown by many studies (37–
40) and was illustrated further by the finding that HIV-1–infected 
cells can clonally expand both prior to and during ART (1, 2, 31), 
resulting in populations of cells with identical proviruses and iden-
tical integration sites in the blood and tissues (1). More recently, 
expanded clones harboring replication-competent proviruses 
were identified by sequence matches between viruses recovered 
in multiple different viral outgrowth cultures, revealing that most 
of the HIV reservoir is maintained by cellular proliferation (4, 5, 
41). Furthermore, proviruses with identical sequences, and thus 
likely to be in cell clones, were reported to be a source for rebound 
viremia after stopping ART (12). Collectively, these studies, along 
with the data shown here, demonstrate that proliferating, infected 
cells are a common mechanism of reservoir persistence that needs 
to be targeted to cure HIV-1 infection.
Our earlier data and those of others on adults (13–17), com-
bined with the current data on children, are inconsistent with the 
idea of ongoing viral replication as a mechanism of HIV reservoir 
maintenance and replenishment in the majority of individuals with 
sustained suppression of viremia on ART. Consequently, the devel-
opment of newer antiretroviral agents to better penetrate putative 
sanctuaries and block ongoing viral replication does not appear to 
be critical for curing HIV-1 infection. Rather, efforts should contin-
ue to focus on the exposure and elimination of immunologically 
hidden reservoir cells that persist in individuals on ART.
Methods
HIV-1 quantification and genetic analyses. HIV plasma RNA levels were 
determined using the Roche Amplicor HIV Monitor assay, version 
1.0 (Roche Diagnostics), or the Abbott Diagnostics RealTime HIV-1 
Figure 3. Comparison of analytical approaches. (A) NJ tree of the sequences from a child (PID ZA004) who started treatment at less than 3 months of age 
and had full viremia suppression for 8.9 years (Supplemental Table 1). This tree is identical to that shown in Figure 1D for the same child. Red triangles indi-
cate single-genome DNA sequences obtained 9 months after ART initiation. Black triangles indicate single-genome DNA sequences obtained 8 years later. 
The distance tree shows that the populations did not shift for 8 years on ART; populations at both time points were almost completely homogeneous, with 
only 8 nucleotide differences in 16,800 bases at baseline and 9 nucleotide differences in 19,200 bases 8 years later. The founder sequences persisted across 
the sampling time points. (B) The same sequences analyzed by BEAST using a strict molecular clock (as in ref. 10) show divergence over time, despite the 
identity of most sequences at both time points. Individual sequences are numbered identically in the 2 trees shown in A and B. (C) Simulated NJ distance 
tree using the estimated HIV evolution rate of 6.24 × 10–4 substitutions/site/month from ref. 10, applying the baseline sequences from the same child as in  
A and B. The simulated tree shows artifactual evolution, while the actual tree shows no evidence of sequence divergence after 8 years of ART.
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ed sequences are generated by applying the model on the consensus 
sequence of the early time point. This model assumes that all muta-
tions at the random sites are equally likely and makes no assumptions 
about the relative frequencies of transversions versus transitions. The 
code is written in C++ and is available from the authors upon request.
Statistics. The test for panmixia is described in Achaz et al. and 
in Kearney et al. (3, 26). A P value significance cutoff of less than 
10–3 was used to account for multiple comparisons as previously 
described (3). A significant change in APD over time was deter-
mined using a 2-tailed, 1-sample t test, where the assumed mean 
was the APD of the early time point and the sample distribution was 
the APD of the late time point, with variance estimation performed 
using 1,000 bootstrap replicates. Significance for the root-to-tip 
distance analysis was determined by linear regression. The variance 
of the observed points about this line was used to calculate the P 
value using a 2-tailed F test based on the null hypothesis that the 
slope of the line was zero.
Study approval. The CHER trial is registered with Clinical 
Trials.gov (NCT00102960). Guardians of all donors provided written 
informed consent, and the study was approved by the IRB of Stellen-
bosch University.
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assay (Abbott Laboratories). HIV DNA levels were determined using 
the integrase cell-associated DNA (iCAD) assay (42). SGS of a por-
tion of p6-RT-RT was performed using plasma virus RNA or PBMC 
DNA as previously described (3, 29, 32, 42, 43), with modifications 
for amplification of subtype C templates using the following PCR 
primers: 1849+ (5′-GATGACAGCATGTCAGGGAG-3′) and 3500– 
(5′-CTATYAAGTCTTTTGATGGGTCATAA-3′); and for nested 
PCR: 1870+ (5′-GAGTGTTGGCTGAGGCAATGAG-3′) and 3410– 
(5′-CAGTTAGTGGTACTATGTCTGTTAGTGCTT-3′). Sequences 
were aligned using ClustalW (http://www.ebi.ac.uk/Tools/msa/
clustalw2/). Sequences that were obviously defective for viral repli-
cation, including those that contained stop codons due to hypermu-
tation, were omitted from downstream analyses. Population genetic 
diversity was calculated as the APD using Molecular Evolutionary 
Genetics Analysis, version 6.0 (MEGA6) (http://www.megasoftware.
net). Shifts in population structure were calculated using a subdivision 
test for panmixia, with a P value of less than 10–3 as the significance 
cutoff (as described by the original report and other publications) to 
account for the high number of comparisons between sequences and 
nucleotide sites (3, 12, 26). The test was derived from a geographic 
population structure test proposed by Hudson et al. (26). NJ trees 
were constructed using MEGA6.
ML tree construction and root-to-tip length calculation. PAUP4.0 
(http://paup.sc.fsu.edu/) was used to construct ML trees. The model 
used in the tree construction was GTR+I+Γ4. Either HIV-1 consensus 
C or the majority sequence from the baseline of the first time-point 
sample sequences were set as the outgroup. Root-to-tip length was cal-
culated on the basis of the ML trees with TreeStat, version 1.6.2, in the 
BEAST package (http://beast.bio.ed.ac.uk/).
BEAST analysis. BEAST, version 1.62 (http://beast.bio.ed.ac.uk/), 
was used to perform time-stamped Bayesian phylogenetic analysis 
using a strict molecular clock (10). HKY-gamma was used as substitu-
tion model. All Markov Chain Monte Carlo (MCMC) chains were run 
at least 100 million steps to ensure good convergence of the param-
eters. Tracer, version 1.5, was used to evaluate the quality of BEAST 
runs (http://beast.bio.ed.ac.uk/tracer).
Simulation of in vivo evolutionary models on sequences. To evaluate 
the accuracy of the evolutionary rate reported in ref. 10, an in-house 
program was generated using the reported evolutionary rate in sub-
stitutions/site/month and the length of time between the sampling 
in 1 child (ZA004) to simulate the expected accumulation of diversity 
that would exist after approximately 8 years on ART if the reported 
evolutionary rate is correct. Given our observations in the 2 replica-
tion controls, the model allowed 50% of the introduced mutations to 
be randomly distributed, while 50% were limited to mutations at spe-
cific sites (reflecting positive selection within cytotoxic T lymphocyte 
[CTL] epitopes, as observed in the controls). The number of mutations 
per sequence was determined via a Poisson distribution. The simulat-
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